Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Nubeqa

- PMLiVE

Bayer to challenge Avastin legal ruling

Both sides claim to be acting in patients' best interest

- PMLiVE

NHS wins legal fight with pharma over off-label Avastin

Industry criticises judgement - fearful of 'undermining regulation' as well as big earning products

Bayer symbol

Bayer roll-out of haemophilia drug Jivi gathers pace

Japan’s MHLW is next to approve the drug

Sanofi reception

Sanofi swaps execs with Bayer, looks to staunch diabetes, cardio decline

Dieter Weinand to be based in key US market

- PMLiVE

Daily Brief: DeepMind and NHS success in AI, Bayer invests in COPD, Alecensa OK in Scotland

The latest from pharma, biotech and healthcare

Bayer symbol

Loxo, Bayer get quick FDA review for ‘precision’ cancer drug

Bayer and Loxo hopeful about novel biomarker-led cancer treatment

- PMLiVE

Shaping healthcare

Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes

Bayer looks to leverage AI across the pharma value chain

Dieter Weinand outlines his hopes for applying artificial intelligence

- PMLiVE

Pharma sales help Bayer escape the worst from a bumpy 2017

But the German pharma firm reins in expectations for this year

Working with our healthcare system more closely is vital

Bayer’s Lars Bruening on partnership working amid environmental challenges

Novartis day

Novartis’ Extavia evades NICE restrictions on MS drugs

But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down

Bayer symbol

Bayer gets clinical data to support $1.5bn Loxo deal

Larotrectinib’s response rate likely to be practice changing

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links